-
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
-
Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has entered into a licensing agreement with fellow pharmaceutical company Livzon Pharmaceutical Group Inc. (HKG: 1513) for the development and commercialization of fadanafil, a Category 1 chemical compound. Under the terms of the agreement,…
-
Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation of an initial public offering (IPO) on Shanghai’s Sci-Tech Innovation Board (STAR) for its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm). Xuanzhu Biopharm, which concentrates on therapeutic areas such as oncology, metabolism, anti-infection, and digestion,…
-
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid…
-
Sihuan Pharmaceutical Restructures with Dual Organization Model
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a dual organization structure consisting of group headquarters and business platform headquarters. Its subsidiaries Xuanzhu Biopharm Co., Ltd and Jilin Huisheng Biopharmaceutical Co., Ltd, two biopharmaceutical companies, will establish themselves as the new business platform headquarters.…
-
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration (NMPA) has accepted a market filing from its non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd for a combination therapy of fulvestrant and piroxetine in advanced breast cancer. This marks Xuanzhu Bio’s first filing for an…
-
Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co., Ltd has received approval to proceed with a Phase II clinical study of anaprazole for the treatment of reflux esophagitis (RE) and associated symptoms, including acid reflux, heartburn, and retrosternal pain. Drug ProfileAnaprazole, the only…
-
Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China
•
China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio’s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).…
